EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Are Terminal Alkynes Necessary for MAO-A/MAO-B Inhibition? A New Scaffold Is Revealed

Panagiou Mavroeidi, Leandros P Zorba iD, Nikolaos V Tzouras, Stavros P Neofotistos iD, Nikitas Georgiou, Kader Sahin, Murat Şentürk, Serdar Durdagi, Georgios C Vougioukalakis iD, Thomas Mavromoustakos iD

Molecules · 2024

DOI: 10.3390/molecules29112486 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2024. Verfasst von Panagiou Mavroeidi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Organic Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, 15771 Athens, Greece. Hauptthemen laut MEDLINE: Alkynes, Monoamine Oxidase, Monoamine Oxidase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hellenic Foundation for Research and Innovation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A versatile family of quaternary propargylamines was synthesized employing the KA2 multicomponent reaction, through the single-step coupling of a number of amines, ketones, and terminal alkynes. Sustainable synthetic procedures using transition metal catalysts were employed in all cases. The inhibitory activity of these molecules was evaluated against human monoaminoxidase (hMAO)-A and hMAO-B enzymes and was found to be significant. The IC50 values for hMAO-B range from 152.1 to 164.7 nM while the IC50 values for hMAO-A range from 765.6 to 861.6 nM. Furthermore, these compounds comply with Lipinski’s rule of five and exhibit no predicted toxicity. To understand their binding properties with the two target enzymes, key interactions were studied using molecular docking, all-atom molecular dynamics (MD) simulations, and MM/GBSA binding free energy calculations. Overall, herein, the reported family of propargylamines exhibits promise as potential treatments for neurodegenerative disorders, such as Parkinson’s disease. Interestingly, this is the first time a propargylamine scaffold bearing an internal alkyne has been reported to show activity against monoaminoxidases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlkynesMonoamine OxidaseMonoamine Oxidase InhibitorsHumansMolecular Docking SimulationMolecular Dynamics SimulationMolecular StructurePargylinePropylaminesStructure-Activity Relationship

Stichwörter der Autor:innen

MM/GBSAmolecular dynamicsmonoaminoxidasespropargylamines

Substanzen

AlkynesMonoamine Oxidasemonoamine oxidase A, humanMonoamine Oxidase InhibitorsPargylinepropargylaminePropylamines

Autor:innen und Institutionen

  • Laboratory of Organic Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, 15771 Athens, Greece.
  • Department of Analytical Chemistry, School of Pharmacy, Bahcesehir University, 34349 Istanbul, Turkey.
  • Department of Biochemistry, Faculty of Pharmacy, Agri Ibrahim Cecen University, 04100 Agri, Turkey.
  • Molecular Therapy Laboratory, Department of Pharmaceutical Chemistry, School of Pharmacy, Bahcesehir University, 34349 Istanbul, Turkey.
  • Computational Biology and Molecular Simulations Laboratory, Department of Biophysics, School of Medicine, Bahcesehir University, 34349 Istanbul, Turkey.
  • Laboratory for Innovative Drugs (Lab4IND), Computational Drug Design Center (HİTMER), Bahcesehir University, 34349 Istanbul, Turkey.

ORCID-Profile: Leandros P Zorba, Stavros P Neofotistos, Georgios C Vougioukalakis, Thomas Mavromoustakos

Förderung

  • Hellenic Foundation for Research and Innovation

Zitieren

APA

Mavroeidi, P., Zorba, L. P., Tzouras, N. V., Neofotistos, S. P., Georgiou, N., Sahin, K., Şentürk, M., Durdagi, S., Vougioukalakis, G. C., & Mavromoustakos, T. (2024). Are Terminal Alkynes Necessary for MAO-A/MAO-B Inhibition? A New Scaffold Is Revealed. Molecules. https://doi.org/10.3390/molecules29112486

Vancouver

Mavroeidi P, Zorba LP, Tzouras NV, Neofotistos SP, Georgiou N, Sahin K, et al. Are Terminal Alkynes Necessary for MAO-A/MAO-B Inhibition? A New Scaffold Is Revealed. Molecules. 2024. doi:10.3390/molecules29112486

BibTeX
@article{Mavroeidi2024,
  author = {Mavroeidi, Panagiou and Zorba, Leandros P and Tzouras, Nikolaos V and Neofotistos, Stavros P and Georgiou, Nikitas and Sahin, Kader and Şentürk, Murat and Durdagi, Serdar and Vougioukalakis, Georgios C and Mavromoustakos, Thomas},
  title = {Are Terminal Alkynes Necessary for MAO-A/MAO-B Inhibition? A New Scaffold Is Revealed},
  journal = {Molecules},
  year = {2024},
  doi = {10.3390/molecules29112486}
}
Kostenlos starten →